Chancery Advances Investors' $1.2B Drug Control Suit
Citing strong allegations of fraud and "oppressive" and "retributive" tactics by Hedgepath Pharmaceuticals controlling stockholder Mayne Pharma, a Delaware vice chancellor on Thursday refused to dismiss a suit accusing Mayne of...To view the full article, register now.
Already a subscriber? Click here to view full article